key: cord-0333699-p2xqurnl authors: Di Germanio, C.; Simmons, G.; Thorbrogger, C.; Martinelli, R.; Stone, M.; Gniadek, T.; Busch, M. P. title: Vaccination of COVID-19 Convalescent Plasma Donors Increases Binding and Neutralizing Antibodies Against SARS-CoV-2 Variants date: 2021-10-30 journal: nan DOI: 10.1101/2021.10.28.21265622 sha: bfaff59c3838adc2e45d44148ebd93a4cca2ab47 doc_id: 333699 cord_uid: p2xqurnl Background: COVID-19 convalescent plasma (CCP) was widely used as passive immunotherapy during the first waves of SARS-CoV-2 infection in the US. However, based on observational studies and randomized controlled trials, beneficial effects of CCP were limited, and its use was virtually discontinued early in 2021, in concurrence with increased vaccination rates and availability of monoclonal antibody (mAb) therapeutics. However, as new variants of the SARS-CoV-2 spread, interest in CCP derived from vaccine-boosted CCP donors is resurging. The effect of vaccination of previously infected CCP donors on antibodies against rapidly spreading variants of concern (VOC) is still under investigation. Study Design/Methods: In this study, paired samples from 11 CCP donors collected before and after vaccination were tested to measure binding antibodies levels and neutralization activity against the ancestral and SARS-CoV-2 variants (Wuhan-Hu-1, B.1.1.7, B.1.351, P.1, D614G, B.1.617.2, B.1.427) on the Ortho Vitros Spike Total Ig and IgG assays, the MSD V-PLEX SARS-CoV-2 Panel 6 arrays for IgG binding and ACE2 inhibition, and variant-specific Spike Reporter Viral Particle Neutralization (RVPN) assays. Results/Findings: Binding and neutralizing antibodies were significantly boosted by vaccination, with several logs higher neutralization for all the variants tested post-vaccination compared to the pre-vaccination samples, with no difference found among the individual variants. Discussion: Vaccination of previously infected individuals boosts antibodies including neutralizing activity against all SARS-CoV-2 VOC, including the current spreading delta (B.1.617.2) variant. Animal model and human studies to assess clinical efficacy of vaccine boosted CCP are warranted, especially since 15-20% of current donations in the US are from previously infected vaccine-boosted donors. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 30, 2021. ; S a m p l e s w e r e f i r s t s c r e e n e d o n t h e O r t h o V i t r o s i n s t r u m e n t ( O r t h o -C l i n i c a l D i a g n o s t i c s , I n c . , s s a y s a g a i n s t t h e S p i k e S 1 p r o t e i n o f t h e v i r u s , a s p r e v i o u s l y d e s c r i b e d 9 . S i n c e m o s t p o s t -v a c c i n a t i o n s a m p l e s r e a c h e d t h e u p p e r l i m i t o f s i g n a l -t o c u t o f f ( S / C O ) v a l u e s r e p o r t e d f o r t h e s e a s s a y s , t h e y w e r e f u r t h e r t e s t e d f o l l o w i n g d i l u t i o n s ( 1 0 -a n d 1 0 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 30, 2021 . t h e u p p e r l i m i t o f d e t e c t i o n f o r e a c h o f t h e a s s a y s w h e n t e s t e d a c c o r d i n g t o t h e E U A i n s t r u c t i o n s f o r u s e , p r o m p t i n g a d d i t i o n a l t e s t i n g f o l l o w i n g s e r i a l d i l u t i o n . A f t e r d i l u t i o n , t h e S / C O f o r t h e T o t a l I g p o s t v a c c i n a t i o n s h o w e d a n a v e r a g e S / C O o f 1 2 , 6 7 0 ( 9 5 % C I 1 0 , 9 1 7 -1 4 , 4 2 3 ) a t 1 : 1 0 a n d S / C O o f 6 7 , 5 2 4 ( 9 5 % C I 3 9 , 8 3 7 -9 5 , 2 1 1 ) a t 1 : 1 0 0 a f t e r a d j u s t i n g f o r t h e d i l u t i o n f a c t o r . f o r t h e I g G a s s a y t h e p o s t -v a c c i n a t i o ) e p r e -v a c c i n a t i o n s a m p l e s s h o w e d n e u t r a l i z i n g a c t i v i t y d u e t o n a t u r a l i n f e c t i o n , e s p e c i a l l y f o r t h e W u h a n -H u -1 s t r a i n , w i t h a m e a n N T 5 0 o f 5 . A f t e r v a c c i n a t i o n , t h e n e u t r a l i z i n g a c t i v i t y i n c r e a s e d s i g n i f i c a n t l y ( p < 0 . 0 0 1 ) a g a i n s t a l l t h e v i r u s v a r i a n t s , w i t h n o s i g n i f i c a n t d i f f e r e n c e s i n t h e l e v e l s o f b o o s t i n g b e t w e e n t h e v a r i a n t s . T h e a v e r a g e N T 5 0 f o l l o w i n g v a c c i n a t i o n w a s 1 0 , 8 3 1 ± 2 , 0 0 0 . S p e a r m a n c o r r e l a t i o n a n a l y s is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 30, 2021. ; a n d i n d e e d o n e d o s e o f t h e n o r m a l t w o -d o s e B N T 1 6 2 b 2 o r m R N A -1 2 7 3 r e g i m e n s i s s u f f i c i e n t t o b o o s t i m m u n i t y 1 3 , 1 4 , 1 5 . W e t h e r e f o r e a s s e s s e d t h e a b i l i t y o f v a c c i n a t i o n t o b o o s t a n t i -S A R S -C o V -2 a n t i b o d y l e v e l s i n p r e v i o u s l y i n f e c t e d C C P d o n o r s , a n d i m p o r t a n t l y d e t e r m i n e d w h e t h e r t h e t i t e r s o f n e u t r a l i z i n g a n t i b o d y a g a i n s t V O C s m a y i n d i c a t e p o t e n t i a l v a l u e i n C C P s p e c i f i c a l l y c o l l e c t e d f r o m v a c c i n a t The AU/ml IgG increases for all the post-vaccination samples, for both S1 and RBD of the Wuhan-Hu-1, but not for NC. Antibodies against all the variants increase similarly after vaccination. The percentage of ACE2 inhibition increases for all the post-vaccination samples, for Wuhan-Hu-1 S1 and RBS, and all the variants tested. There is no significance difference among all the variants, neither before, nor after vaccination. (**= 0.001, ***=0.0005, ****= <0.0001). . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) A f t e r v a c c i n a t i o n , t h e N T 5 0 w e r e s i g n i f i c a n t l y h i g h e r a n d c o m p a r a b l e a c r o s s v a r i a n t s . (*=0.05, **= 0.001, ***=0.0005). . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted October 30, 2021. ; https://doi.org/10.1101/2021.10.28.21265622 doi: medRxiv preprint Effectiveness of convalescent plasma therapy in severe COVID-19 patients A Little) Clarity on Convalescent Plasma for Covid-19 Early Convalescent Plasma for High-Risk Outpatients with Covid-19 Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization Outbreak of SARS-CoV-2 Infections Vaccine Breakthrough Infections, Associated with Large Public Gatherings -Barnstable County SARS-CoV-2 antibody persistence in COVID-19 convalescent plasma donors: Dependency on assay format and applicability to serosurveillance. Transfusion (Paris) SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant -National Healthcare Safety Network SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors